Keep an eye on Intently (2)pentobarbital will lessen the extent or effect of suvorexant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Sturdy CYP3A4 inducers may lower suvorexant efficacy; if amplified suvorexant dose necessary, tend not to exceed twenty mg/working daypentobarbital and olopatadine intranasal ea